Table III.

Study of links between blood calprotectin level in patients with juvenile idiopathic arthritis (JIA) prior to discontinuation of treatment and flare risk

Follow-up	Total	Gender (male/female)	Flare development, number (abs., %)	Calprotectin level in patients with JIA at visit 0 (ng/ml, median [min–max]), who
				Developed a flare	Did not develop a flare
At 3 months	54	17/37	5 (9.3%)	1,700 (920–24,000)	1,500 (200–30,000)
				p** = 0.35
At 6 months	53*	17/36*	8 (15.1%)	1,500 (200–30,000)	1,500 (200–30,000)
				p** = 0.619
At 12 months	53*	17/36*	21 (39.6%)	1,300 (200–30,000)	1,650 (200–11,200)
				p** = 0.34

^*One patient withdrew from the study at 3 months, ^** Mann-Whitney criteria.